Magnesium Has Not Been Proven to Improve RLS as Add-On Therapy
Magnesium supplementation is not recommended for RLS treatment based on the most recent and authoritative evidence—the 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline does not include magnesium among its treatment recommendations for adults with RLS 1.
Why Magnesium Is Not Recommended
The 2025 AASM guideline comprehensively reviewed available treatments for RLS and made explicit recommendations for and against specific therapies. Notably absent from this guideline is any mention of magnesium, despite the guideline addressing numerous other supplements and medications 1. This omission is significant because:
- The guideline specifically evaluated and made recommendations about other supplements (ferrous sulfate, dipyridamole, vitamin C for ESRD patients) 1
- The guideline even made recommendations against certain treatments like valerian 1
- If magnesium had sufficient evidence, it would have been included
What the Research Actually Shows
While some recent research studies suggest potential benefits, the evidence remains insufficient:
Positive but Limited Studies:
- A 2024 open-label pilot study (n=12) showed magnesium citrate 200mg daily improved RLS symptoms and sleep quality 2
- A 2022 single-blind trial found magnesium oxide 250mg daily improved symptoms, with greater effectiveness than vitamin B6 3
- A 2024 systematic review suggested magnesium oxide and vitamin B6 may improve sleep quality 4
Critical Limitations:
- A 2019 systematic review concluded: "We were unable to make a conclusion as to the effectiveness of magnesium for RLS/PLMD" 5
- A 2026 systematic review on magnesium for sleep found "current evidence does not support oral magnesium as a routine treatment for insomnia" with "low to very low" certainty of evidence 6
- The positive studies are small, open-label, or single-blind designs with high risk of bias 4
Genetic Evidence:
Recent 2025 Mendelian randomization analysis suggests higher genetically predicted magnesium levels may be associated with lower RLS risk (OR 0.62), but this represents population-level genetic associations, not proof of treatment efficacy 7.
What You Should Do Instead
Follow the 2025 AASM guideline recommendations 1:
First-Line Treatments (Strong Recommendations):
- Gabapentin enacarbil
- Gabapentin
- Pregabalin
- IV ferric carboxymaltose (if appropriate iron parameters)
Second-Line Options (Conditional Recommendations):
- Oral ferrous sulfate (if appropriate iron parameters) 1
- Dipyridamole 1
- Extended-release oxycodone and other opioids 1
Treatments to Avoid Long-Term:
The guideline suggests against standard use of dopamine agonists (pramipexole, ropinirole, rotigotine) due to augmentation risk, though they may be used short-term in select patients 1.
Clinical Bottom Line
Do not add magnesium to current RLS treatment based on the hope it will improve symptoms. The 2025 AASM guideline—the highest quality, most recent evidence—does not support its use. If your patient's current treatment is inadequate, optimize therapy using proven first-line agents (alpha-2-delta ligands or IV iron) rather than adding unproven supplements. The research on magnesium remains preliminary, inconsistent, and of insufficient quality to justify clinical use 6, 5.